Anzeige
Meldung des Tages: 1 Billion Dollar reichen nicht: Europas kritisches Rohstoffproblem

Inventiva Aktie News

Aktie
WKN:  A2DLV9 ISIN:  FR0013233012 US-Symbol:  IVEVF Branche:  Biotechnologie Land:  Frankreich
5,69 €
-0,07 €
-1,22%
07:30:54 Uhr
Depot/Watchlist
Marktkapitalisierung *
328,73 Mio. €
Streubesitz
40,63%
KGV
-4,80
Index-Zuordnung
-

Inventiva News

26.01.26 - GlobeNewswire
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Daix (France), New York City (New York, United States), January 26, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) (“ Inventiva ” or the “ Company ”), a clinical-​stage ...
17.12.25 - GlobeNewswire
Inventiva to Present at the 44th Annual J.P. Morgan Healthcare Conference
Daix (France), New York City (New York, United States), December 17, 2025  – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-​stage ...
28.11.25 - GlobeNewswire
Results of the Votes of the Combined Shareholders’ General Meeting of November 27, 2025
Daix (France), New York City (New York, United States), November 28, 2025  – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-​stage biopharmaceutical company ...
24.11.25 - GlobeNewswire
Information relating to the stabilization activities carried out in the context of its recent offering
Daix (France), New York City (New York, United States), November 24, 202 5 – Publication of information relating to the stabilization activities carried out in the context of the recent ...
21.11.25 - GlobeNewswire
Inventiva reports 2025 Third Quarter Financial Information¹
Cash and cash equivalents at €97.6 million, and €24.7 million in short-​term deposits 2 as of September 30, 2025. Revenues of €4.5 million for the first nine months of 2025. Cash ...
17.11.25 - GlobeNewswire
Inventiva announces full exercise of Underwriters’ Option, bringing proceeds of Offering to approximately $172.5M
Daix (France), New York City (New York, United States), November 17, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (" Inventiva " or the " Company "), a clinical-​stage ...
13.11.25 - GlobeNewswire
Inventiva announces pricing of upsized public offering of approximately $150M of American Depositary Shares
Daix (France), New York City (New York, United States), November 13, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (" Inventiva " or the " Company "), a clinical-​stage ...
12.11.25 - GlobeNewswire
Inventiva announces launch of public offering
Daix (France), New York City (New York, United States), November 12, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (" Inventiva " or the " Company "), a clinical-​stage ...
06.11.25 - GlobeNewswire
Combined General Meeting of November 27, 2025 - Availability of the preparatory documents
Daix (France), New York City (New York, United States), November 6,  2025 – Inventiva (Euronext Paris and Nasdaq : IVA) (“ Inventiva ” or the “ Company ”), a clinical-​stage ...
06.11.25 - GlobeNewswire
Statement of total voting rights and shares forming the company’s share capital as October 20, 2025
Article R. 22-10-23 of the French Commercial Code Market : Euronext Paris ISIN code / Mnemo : FR0013233012 / IVA Web site : www . i n v e n t i v a p ha r m a. c om Date Number ...
14.10.25 - GlobeNewswire
Inventiva Announces the Implementation of a New ATM Program
Daix (France), New York City (New York, United States), October 14, 2025 – Inventiva (Euronext Paris and Nasdaq : IVA) (“ Inventiva ” or the “ Company ”), a clinical-​stage ...
07.10.25 - GlobeNewswire
Inventiva to Present Multiple Abstracts at AASLD The Liver Meeting® 2025
Presentation of a comparison between digital and glass slide histology from screening biopsies in the Phase 3 NATiV3 study Presentation of digital pathology data from preclinical ...
01.10.25 - GlobeNewswire
Inventiva Appoints Andrew Obenshain as Chief Executive Officer
Daix (France), New York City (New York, United States), October 1, 2025  – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-​stage biopharmaceutical ...
29.09.25 - GlobeNewswire
Inventiva reports its unaudited 2025 first-half financial results and provides a corporate update  
Cash and cash equivalents at €146.7 million including €24.6 million in short-​term deposits 1 as of June 30, 2025 Receipt of the gross proceeds of €115.6 million from the second ...
24.09.25 - GlobeNewswire
Inventiva to Host Analyst and Investor Event on October 8, 2025
Program will include an update on the Company’s lead asset, lanifibranor, ahead of anticipated Phase 3 NATiV3 topline results in the second half of 2026 Three renowned ...
04.09.25 - GlobeNewswire
Inventiva to Participate in Upcoming September Investor Conferences
Daix (France), New York City (New York, United States), September 4, 2025  – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-​stage ...
11.08.25 - GlobeNewswire
Inventiva to Participate in Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
Daix (France), New York City (New York, United States), August 11, 2025  – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-​stage biopharmaceutical ...
31.07.25 - GlobeNewswire
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Daix (France), New York (New York, United States), July 31, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“ Inventiva ” or the “ Company ”), a clinical-​stage biopharmaceutical ...
29.07.25 - GlobeNewswire
Inventiva Reports Preliminary 2025 First-Half Financial Information¹
Cash and cash equivalents at €122.1 million and €24.6 million in short-​term deposits 2 as of June 30, 2025 Revenues of €4.5 million recorded in H1 2025 Daix (France), New York City ...
09.07.25 - GlobeNewswire
Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance
Jason Campagna, MD, PhD, joins Inventiva as President of R&D and Chief Medical Officer, succeeding Pierre Broqua, PhD, and Michael Cooreman, MD Martine Zimmermann, ...

Newssuche

Videos

newspaper
27.01.26 -13,00%
Technical Trading: Pfund Short
GBP/USD Short Typ: Turbo Open End WKN: VH3A2E Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »